NCT02196818

Brief Summary

This is a multi-centre, prospective post marketing surveillance study to assess mid-term performance of the Mpact cup in subjects requiring primary total hip arthroplasty.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2013

Longer than P75 for all trials

Geographic Reach
1 country

4 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

July 7, 2014

Completed
15 days until next milestone

First Posted

Study publicly available on registry

July 22, 2014

Completed
6.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2022

Completed
Last Updated

March 22, 2023

Status Verified

March 1, 2023

Enrollment Period

8.1 years

First QC Date

July 7, 2014

Last Update Submit

March 20, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • The Kaplan-Meier analysis as a measure of implant performance.

    5 years

Secondary Outcomes (2)

  • The Harris Hip Score.

    pre-op, 3/6 months, 1,2 and 5 years

  • Radiological analysis as a meausure of safety.

    3/6 months, 1,2 and 5 years

Study Arms (1)

Mpact Acetabular Shell

Monitor the performance of the Mpact cup in the treatment of patients with hip joint disease requiring a total hip replacement.

Device: Mpact Acetabular Shell

Interventions

Total Hip Replacement

Mpact Acetabular Shell

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

primary total hip arthroplasty

You may qualify if:

  • Patients who are willing and able to provide written informed consent for participation in the study. Written informed consent must be obtained prior to the patient's surgery.
  • Those presenting with disease that meets the indications for use for Medacta USA implants defined by this study (on-label use).
  • Patients must be willing to comply with the pre and post-operative evaluation schedule.

You may not qualify if:

  • Those with one or more medical conditions identified as a contraindication defined by the labeling on any Medacta implants used in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Vail Orthopedics, P.C.

Denver, Colorado, 80230, United States

Location

Saint Alphonsus Regional Medical Center

Boise, Idaho, 83702, United States

Location

Illinois Bone & Joint Institute, LLC

Libertyville, Illinois, 60048, United States

Location

Jordan Valley Medical Center

West Jordan, Utah, 84088, United States

Location

MeSH Terms

Conditions

OsteoarthritisArthritisOsteonecrosisHip Dislocation, Congenital

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal DiseasesRheumatic DiseasesBone DiseasesNecrosisPathologic ProcessesPathological Conditions, Signs and SymptomsDevelopmental Dysplasia of the HipMusculoskeletal AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 7, 2014

First Posted

July 22, 2014

Study Start

March 1, 2013

Primary Completion

April 1, 2021

Study Completion

April 1, 2022

Last Updated

March 22, 2023

Record last verified: 2023-03

Locations